Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 28-Nov-2022 14:52:31

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Ambulance Trusts
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • Acute Trusts
  • NHS Trusts (England) - Chief Executive

Action category: Action

Title: Remdesivir for patients hospitalised due to COVID-19

Broadcast content: The published policy has been updated to reflect remdesivir’s extended market authorisation to now cover adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment), and following consideration of the recommendations of the updated World Health Organization clinical guideline. The linked clinical guide, summarising the main COVID treatment options available to patients admitted to hospital due to COVID, has been updated accordingly to support clinical decision making.  

Additional information: This alert does not need to be cascaded to Primary Care

Alert reference: CEM/CMO/2022/016


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency